Replies to post #20963 on Mymetics Corp (MYMX)

[Work Harder]

I still maintain that

It's not that long to wait to find out

Much less time than it has been for this year

:}

[Work Harder]

The virosome formulations will incorporate and evaluate two different SARS-CoV-2 antigens, one full length stabilized S protein, for which Mymetics is collaborating with the group of Dr. Rogier Sanders at the Amsterdam Medical Center of the University of Amsterdam, the Netherlands, and the second is a receptor binding domain recombinant protein of SARS-CoV-2.

Do you see what the man (Dr Kempers) is trying to tell you b/c it isn't the first time we round about heard that

If the gal @ Baylor see's what she wants then we could be in a good place here

Any Hiv update could be telling, imho

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159243451

:}

[Work Harder]

Release of Immunomodulatory Ebola Virus
Glycoprotein-Containing Microvesicles Is
Suppressed by Tetherin in a Species-Specific
Manner

Virosome 133 times

Highlights

The Ebola virus glycoprotein (GP) drives the release of GP-containing virosomes

Tetherin restricts GP-virosome release through
transmembrane domain interactions

GP-virosome release is most efficient for GPs of highly
pathogenic Ebola viruses

Immunomodulatory GP-virosomes serve as decoys for
EBOV-neutralizing antibodies

2 Institute of Virology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health, 85764 Neuherberg, Germany

ACKNOWLEDGMENTS

We would like to thank Gerhard Jahn and Thomas Iftner for constant supportand encouragement and Ulrike Protzer for providing continued access to the research facilities at the Helmholtz Center Munich. Furthermore, we thank Daniel Sauter, Paul Bieniasz, and Thomas Gramberg for providing reagents and Thomas Hoenen for the trVLP system. This work was funded by grants to S.P. and M. Schindler from Deutsche Forschungsgemeinschaft (SCHI1073/4-1 and PO 716/8-1). Furthermore, M. Schindler received institutional
support from the Helmholtz Center Munich, German Research Center for Environmental Health, and the University Hospital Tuebingen.

https://www.cell.com/cell-reports/pdf/S2211-1247(19)30094-4.pdf

From PR Today

Helmholtz Center of Infection Research (HZI) in Germany

https://www.helmholtz.de/en/about_us/helmholtz_centers/

The Helmholtz Association pursues the long-term research goals of the state and society, including basic research, in scientific autonomy. To do this, the Helmholtz Association conducts top-level research to identify and explore the major challenges facing society, science and the economy. Its work is divided into six research fields. The Helmholtz Association brings together 19 scientific-technical and biological-medical research centers. With more than 42,000 employees and an annual budget of over € 5 billion, the Helmholtz Association is Germany's largest scientific organisation. The Association's work follows in the tradition of its namesake, the natural scientist Hermann von Helmholtz (1821-1894).

https://www.helmholtz.de/en/about_us/

Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice.

Affiliations

6 authors

1. Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.

2 authors

2. Department of Research and Development, Haukeland University Hospital, Bergen, Norway.

1 author

3. Institute of Virology and Immunology, Mittelhäusern, Switzerland.

https://europepmc.org/article/pmc/5624999